If you came here from a Google search, you probably typed something like "how much weight will I actually lose on Ozempic" — and you've already noticed the internet has approximately one million answers, most of which are either marketing copy or anecdote. This guide is the realistic version: what the trials actually showed, what real users actually experience, and where you should expect the curve to flatten.
GLP-1s drive weight loss through a few overlapping mechanisms — appetite suppression, slowed gastric emptying, better blood-sugar stability, and reduced reward signaling around food. The mechanisms produce a curve that's predictable in shape but variable in magnitude. The variability is the part most "X pounds in Y weeks" content gets wrong.
The big picture
Two studies anchor most of what we know about GLP-1 weight loss outcomes:
| Trial | Drug | Dose | Duration | Mean weight loss |
|---|---|---|---|---|
| STEP-1 | Semaglutide | 2.4 mg/wk | 68 weeks | 14.9% |
| SURMOUNT-1 | Tirzepatide | 15 mg/wk | 72 weeks | 22.5% |
Both trials enrolled adults with obesity (BMI ≥ 30, or ≥ 27 with a comorbidity) but without diabetes. Adding diabetes to the picture changes the numbers — diabetic users typically lose somewhat less, all else equal, because the underlying metabolic dysfunction blunts the drug's effect.
Real-world results tend to land slightly below trial numbers, mostly because trial protocols force adherence and titration rigor that real clinics can't replicate. The honest band:
- Semaglutide at 2.4 mg/wk: 10–18% loss over a year, with a long right tail of higher-responders
- Tirzepatide at 15 mg/wk: 15–22% loss over a year, with a similar high-responder tail
- Both at sub-maintenance doses: less, proportional to where you stop
For deeper coverage of how each molecule works, see the semaglutide pillar and tirzepatide pillar.
The realistic timeline
Most users want a month-by-month preview. Here's what's typical at the maintenance dose of either drug:
| Time on drug | Cumulative weight loss | What's driving it |
|---|---|---|
| Week 1–4 | 1–4 lbs | Mostly appetite, water shifts |
| Month 2 | 4–8 lbs | Real fat loss begins as titration progresses |
| Month 3 | 6–12 lbs | Steady curve at higher doses |
| Month 6 | 10–18% of starting weight | Often the steepest stretch |
| Month 12 | 14–22% of starting weight | Approaches trial averages |
| Month 18+ | Plateau near a new setpoint | Body adapts; weight stabilizes |
Two important footnotes. First, the first month is appetite, not weight. People who weigh themselves daily in week 2 and panic that "it's not working" are looking at the wrong signal — appetite suppression is the leading indicator, scale movement lags by 2–4 weeks. Second, the curve is rarely linear. Most users go through one or two visible plateaus over the year, and the plateaus are not failures.
For the full month-by-month breakdown, see what weight loss to expect by month.
Plateaus: when, why, what to do
Stalls are the second-most-asked question after "how much." A few patterns:
- The week-2 false alarm. No real weight loss yet. Wait for the titration to do its work.
- The month-2 plateau. Often coincides with stepping up doses; metabolic adaptation kicks in. Usually resolves with the next dose increase.
- The month-6 plateau. Real metabolic adaptation. Body has adjusted setpoint downward; further loss requires either a higher dose, tighter intake, or simply accepting the new weight.
- The month-12+ plateau. This is often the biological floor for a given dose. Pushing past it usually requires switching molecules or accepting the new normal.
Strategies that actually move the needle on a real plateau:
- Hold the line on protein. 1g per pound of goal body weight is a reasonable target. Underfueling muscle causes recomposition stalls.
- Add resistance training if you haven't. Weight loss without resistance training tends to lose more muscle than necessary, which lowers metabolic rate and accelerates plateau.
- Step up the dose if you're not yet at the maintenance ceiling.
- Consider switching molecules if you've been at the ceiling for months without progress (sema → tirz is the most common direction).
- Audit calorie creep. GLP-1s reduce hunger; they don't override decisions to eat. Hidden 200-kcal-a-day creep stalls progress.
Detailed playbook: why weight loss stalls and what works.
What happens when you stop
This is the conversation most prescribers don't have early enough. The trials are clear: stopping cold reliably produces regain.
The cleanest data is STEP-4, an extension trial of STEP-1. Participants who reached the maintenance dose were re-randomized at week 20 to either continue semaglutide or switch to placebo. The continuation group kept losing weight; the placebo group regained roughly two-thirds of their lost weight by week 68.
This isn't a moral failing or a willpower issue. The drug works by amplifying satiety signaling. Remove the drug, and the signaling returns to baseline — which, for someone with obesity, was a baseline of inadequate satiety in the first place. Coupled with the natural tendency of the body to defend its previous setpoint, regain is the default trajectory.
A few things that change the picture:
- Maintenance dosing. Some clinicians taper to a lower weekly dose rather than stopping entirely. Pharmacologically plausible, evidence-light. See our microdosing evidence review for the data picture.
- Body-composition work during loss. If you preserved muscle through resistance training and adequate protein, your maintenance metabolic rate is higher than it would be otherwise — meaning maintenance is easier even after stopping.
- Behavior changes that stuck. Some users find the drug taught them new defaults — smaller portions, less reward eating — that persist somewhat after stopping. This effect is real but variable.
Full coverage: will I gain the weight back?
How GLP-1 weight loss compares to other approaches
Useful context if you're weighing options:
| Approach | Typical 12-month loss | Notes |
|---|---|---|
| Diet alone (low-cal) | 5–8% | Most regain it within 2–3 years |
| Diet + structured exercise | 7–10% | Slightly better retention |
| Bariatric surgery | 25–35% | Most durable, also most invasive |
| Semaglutide (2.4 mg) | 14–18% | Effective while taken |
| Tirzepatide (15 mg) | 18–22% | Currently the highest-effect FDA-approved option |
| Retatrutide (in trials) | 24%+ | Not yet FDA-approved |
GLP-1s land in the middle — meaningfully better than diet, meaningfully less invasive than surgery, with the trade-off of being chronic medications rather than one-time interventions.
Body composition: are you losing the right kind of weight?
A genuine concern, not just an aesthetic one. All weight loss methods cause some lean mass loss alongside fat loss. The question is the ratio.
Trial data suggests ~25–40% of weight lost on semaglutide is lean mass — fairly typical for any rapid weight loss intervention. Tirzepatide may be slightly better. The lean-mass piece matters because muscle is the primary determinant of resting metabolic rate; losing it makes maintenance harder and increases regain risk.
The interventions that protect lean mass are unsurprising:
- Adequate protein (most users undereat protein on a GLP-1 because everything seems harder to eat)
- Resistance training, even minimal — twice-weekly heavy lifting protects most of what's losable
- Slower titration when possible — gentler weight loss preserves more lean tissue
Detailed: are you losing fat or muscle? (coming soon)
Goal-setting: how much should you aim to lose?
Less than you think, often. The metabolic and cardiovascular benefits of weight loss are mostly captured in the first 5–10%. By 15%, you're past the bulk of the medical benefit. Beyond that, additional loss is mostly about appearance and personal preference, with diminishing returns and rising risk of overshooting into "Ozempic face" and excessive lean-mass loss.
A reasonable framing for goal-setting:
- 5–10% loss: significant medical benefit, modest visible change
- 10–15% loss: substantial medical benefit, visible change, sustainable
- 15–20% loss: maximal medical benefit; appearance changes more pronounced
- >20% loss: appearance-driven; harder to sustain; comes with cosmetic costs
For more on setting a realistic target, see what weight should I aim for? (coming soon)
Where to go from here
The cluster pages below dig into each piece in more depth. Most users come back to them in this order: timeline (what to expect), plateau (when stuck), regain (when planning to stop). That's how the slate is organized.
The bigger picture: GLP-1s work, but how much they work depends on how you use them, what you do alongside them, and how realistic your starting expectations are. Aim for the middle of the typical band, plan for the curve to flatten, and you'll be in the same neighborhood as everyone else who has used these drugs successfully.